Array Biopharma Inc Investor Reception at ESMO 2017
Llamada en conferencia Array Biopharma Inc
Array Biopharma Inc Conference call or earnings call will be held on 09-sep-2017 via an 800 number (toll-free). During the earnings conference call's session Array Biopharma Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Array Biopharma Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma, or MM, and two partnered cancer drugs, selumetinib, partnered with AstraZeneca, and binimetinib (MEK162), partnered with Novartis. Our most advanced wholly-owned clinical stage drugs include: Proprietary Program Indication Clinical Status 1. Filanesib Kinesin spindle protein, or KSP, inhibitor for MM Phase 2 2. ARRY-797 p38 inhibitor for Lamin A/C-related dilated Phase 2 cardiomyopathy, or LMNA-DCM 3.Leer más Llamada en conferencia